I'm taking this tablet, but I don't trust you
Washington, DC (PRWEB) October 30, 2007
Johannesburg Aids Support Group V-1 Trials, Phase I
Completed 17 October 2007
Bangkok, Thailand (PRWEB) October 30, 2007 -- Today Glenda, A Coordinator of the Aids Support Group, talked about her Experiences with Phase I of the V-1 Study. She said she was ecstatic with the lab results, and equally excited about the observable physical and psychological improvements revealed in her clients who participated in the V-1 Study.
With tears streaming down her face, she begged Roger, one of the representatives from Immureboost Company, for more V-1 supplements. She told the representative she is receiving constant requests for V-1 from HIV/AIDS sufferers throughout Greater Johannesburg and beyond.
She pleaded that she now realizes that she has something to help the community that she loves and withholding the V-1 Immureboost supplement from them is impossible for her to do. She explained that she met thousands of people asking for the new V-1 supplements. She pleaded with the Immureboost representatives to send more free supplements as their organization could not financially support all the requests.
While leaving the Aids facility today Roger was confronted by Representatives from the AIDS Consortium in South Africa. They are a network of more than 1000 members, including 300+ community-based organizations focusing on HIV/AIDS related issues in South Africa. They had heard Roger was going to be on the site today, and came to implore him to make a presentation at this week's Consortium conference.
The word is out Glenda said and our phones are besieged by hospital nurses, private physicians, and community organizations. Seven years ago, in response to a lack of family and other support services for people living with the HIV virus in Johannesburg; Glenda formed an Aids Support Group.
Glenda, founder and current coordinator-in-chief, began with her first patient, who was first diagnosed in 1989, and has lived with the virus for over 19 years.
Their foundation believes in a holistic approach to caring for the HIV community, and follows its Mission Statement by offering a range of services to clients that include.
- A Safe Haven
- Support Structure
- Home-Based Care
- Supervision (adherence)
Glenda's reputation for exploring alternative therapies to control the disease within individuals and to slow its spread within the community heavily influenced our decision to approach her with the idea of hosting the initial V-1 Trial in Southern Africa.
Due to the known side effects of antiretroviral (ARV) treatments, many of her clients were reluctant to avail themselves of ARV treatments. Partially due to that reluctance, Glenda and her associates cautiously agreed to an initial 45-day V-1 immunitor pills trial for 15 clients.
The impressive results demonstrated in the few individuals who
participated in Phase I have resulted in Glenda and her staff's enthusiastic propulsion into Phase II, a second 45-Day Trial including persons involved in Phase I and a new group of 15 additional clients, plus a waiting list for persons wishing to join Phases III and beyond.
The Selection Process
Entering Phase I, we had to balance the requirements of the Study with the reality that we did not control the group nor the individuals involved. We were dependent on Glenda to select the persons for Phase I, because she knew the individuals and the group dynamics, and we did not. We provided the expectations and supervision, and relied heavily on Glenda for many specifics.
Our learning curve included becoming conversant with AIDS / HIV medical terminology unique within the local AIDS / HIV community. In addition, we had limited experience working with the hardcore poor, and were appalled at lifestyles we barely knew existed
During Phase I, however, we interacted daily with everyone, and learned to know them as individuals and as members of the group dynamic. We virtually lived at the site for eight weeks, became well-acquainted with every staff member and also with many of the non-Study clients. We have chatted with dozens of them about all subjects, eaten meals with them daily, and earned their trust, which was not an easy process.
We will be intimately involved in the selection process and in the Daily adherence to protocol for Phases II and beyond. We understand that persons with mental illness, alcohol or substance abuse, or a history of non-compliance with group rules are less likely to follow the regimen required to accurately test the efficacy of V-1.
Persons who will be allowed to be in the pool from which names will be drawn for Phase II will have undergone a pre-screening process, designed to assure regimen compliance and commitment to complete the Study, and will sign a pledge to commit to the criteria.
With the exception of the above criteria, no attempt will be made to alter the results of future testing. Our sole goal is to assure the validity of the tests, not to influence the results.
At the inception of Phase I, due to a remodeling project, the Foundation was housed in temporary offices, presenting the staff and us with abnormal challenges, and causing staff inefficiencies, lack of space for staff-client interaction, shortage of computers and other office equipment for processing of test data. Because permanent location of clients' files was temporarily decentralized, staff and we lost valuable time looking for hard copy information, resulting in double and triple entry of data that should have been a single entry computerized process.
Fortunately, the Group has moved back into their permanent facility prior to the inception of Phase II, which will greatly minimize, and hopefully eliminate the administrative problems encountered in the initial Phase.
Secondly, because the Group was so impressed with the obvious improvements in the lives of the Phase I participants, the foundation allocated a separate, dedicated and secure workspace for the computerized recording of Phase II test data.
Initially, Glenda was optimistic about V-1, but cautious, as befits her administrative responsibilities. Soon after the trial began, however, the naysayers came out of the woodwork, and pounced on her. She, the staff and the clients' concerns about the safety of the product increased exponentially as the negatives poured in. As one of the clients aptly stated, "I'm taking this tablet, but I don't trust you". Immediately thereafter, she resolved to take our daily V-1 dosages with the group.
Our open participation helped ease some fears, but the turning point was one particular client who joined the Study in Week 4 of the 45 day trial. Her Cd4 count was 78 and she weighed 30 kg. Within one week, she gained an incredible 15 kgs. Immediately, the fears were replaced with trust. At the end of Phase I she had retained her weight and her Cd4 increased to 130, and the group's trust in V-1 and in us remains solid as we enter Phase II.
Of the seven adults who completed Phase I, six of the Cd-4 counts went up. The improbability of those results (+34, +45, +62, +74, +116,+236) being random is statistically off the charts.
In general, over the course of the study, clients experienced fewer and less intense mood swings, demonstrated improved appetites and physical appearance, increased their liquid consumption and felt more energy and a better outlook on life.
As the results become public knowledge, and the Aids Support Group is being inundated with persons wanting to be included in future Phases, including persons who wish to remain on their ARV holidays in order to join the Study.
An interesting twist resulting from the publicity is that there are
persons within the AIDS / HIV community who do not want to take V-1 for fear that their C-d 4 cell count will increase beyond 200, and they will lose their government pension.
The first phase of the clinical trials in South Africa proved to be beyond anyone's expectations.
Anyone interested in the particulars should contact the company or visit our web site at http://www.immureboost.com/